The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country.

Statement of Results status for the study
Name of Company: ViiV Healthcare
Study No: EPI40670/WWE115682 (EudraCT#2011-003303-38)
Product: GSK2248761
Title: Observational Drug Exposure Registry for Long-Term Follow-Up of Subjects Exposed to GSK2248761
Phase: N/A
Study Period: 29-Jul-2011 to August 30-Apr-2013
Centers: 19
Number of Subjects: 19
Publications: Vani Vannappagari, Amy Sessoms, David Margolis, Lloyd Curtis, Kenne Mountford, Bess Villeponteaux, Tamara Murry, Margaret Richards. "Drug Exposure Registry to Monitor Safety of Investigational Product" (Poster). 29th ICPE (International Conference on PharmacoEpidemiology). Montreal, Canada; August 25-28, 2013.
Statement on results availability: The objective of the study was to collect and monitor data on all subjects who previously received GSK2248761 while enrolled in the Phase 2b studies SGN113399 or SGN113404, evaluating GSK2248761. The study population for the current study was expected to consist of subjects originating from the Phase 2b study sites located in the United States, Romania, France, and Germany However, the study was able to enroll subjects only from the US and not from the European countries since the sites/eligible participants declined participation in this study. Study results summary was posted on clinicaltrials.gov under NCT01458132. Since the study did not have any EU participants, result summary is not posted on EU CTR.